European Commission approves Roche’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs